Lation of p65/RelA in human mammary epithelial cells. Mutat Res. 2014;768:7483. 21. Jung KT, Lim KJ. Curcumin, COX2, and protein p300/CBP. Korean J Pain. 2014;27:365.22. Garc Rivera D, Delgado R, Bougarne N, Haegeman G, Vanden BW. Gallicacid indanone and mangiferin xanthone are robust determinants of immunosuppressive antitumour effects of Mangifera indica L. bark in MDAMB231breast cancer cells. Cancer Lett. 2011;305:2131. 23. Kim HN, Kim DH, Kim EH, et al. Sulforaphane inhibits phorbol esterstimulated IKKNFB signaling and COX2 expression in human mammary epithelial cells by targeting NFB activating kinase and ERK. Cancer Lett. 2014;351:4149. 24. Xia Y, Shen S, Verma IM. NFB, an active player in human cancers. Cancer Immunol Res. 2014;2:823830. 25. Karin M, BenNeriah Y. Phosphorylation meets ubiquitination: the control of NFB activity. Annu Rev Immunol. 2000;18:621663. 26. Pal HC, Sehar I, Bhushan S, Gupta BD, Saxena AK. Activation of caspases and poly (ADPribose) polymerase cleavage to induce apoptosis in leukemia HL60 cells by Inula racemose. Toxicol In Vitro. 2010;24:15991609. 27. Xu R, Zhou G, Peng Y, Wang M, Li X. Pharmacokinetics, tissue distribution and excretion of isoalantolactone and alantolactone in rats following oral administration of radix inulae extract. Molecules. 2015;20:77197736. 28. Wang J, Cui L, Feng L, et al. Isoalantolactone inhibits the migration and invasion of human breast cancer MDAMB231 cells by means of suppression of the p38 MAPK/NFB signaling pathway. Oncol Rep. 2016;36:12691276. 29. Li Z, Qin B, Qi X, Mao J, Wu D. Isoalantolactone induces apoptosis in human breast cancer cellsvia ROSmediated mitochondrial pathway and downregulation of SIRT1. Arch Pharm Res. 2016;39:14411453. 30. Fan Y, Weng Z, Gao H, et al. Isoalantolactone enhances the radiosensitivity of UMSCC10A cells via certain inhibition of Erk1/2 phosphorylation. PLoS A single. 2015;ten:e0145790. 31. Yu Z, Guo W, Ma X, et al. Gamabufotalin, a bufadienolide compound from toadvenom, suppresses COX2 expression via targeting IKKbeta/NFkappaB signaling pathway in lung cancer cells. Mol Cancer. 2014;13:203. 32. Jiang J, Dingledine R. Part of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther. 2012;344:360367. 33. Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28:45314538. 34. Hu Q, Hou YC, Huang J, Fang JY, Xiong H. Itraconazole induces apoptosisand cell cycle arrest via inhibiting hedgehog signaling in gastric cancer cells. J Exp Clin Cancer Res. 2017;36:50. 35. Karin M, Greten FR. NFkappaB: linking inflammation and immunity to cancer improvement and progression. Nat Rev Immunol. 2005;5:749759. 36. Sun SC, Ley SC. New insights into NFkappaB regulation and function. Trends Immunol. 2008;29:469478. 37. Muneeswaran G, Kartheeswaran S, Muthukumar K, Karunakaran C. Temperaturedependent conformational dynamics of cytochrome c: implications in apoptosis. J Mol Graph Model. 2017;79:140148. 38. Wang D. Prostaglandins and cancer. Gut. 2006;55:115122. 39. Jiang J, Dingledine R. Prostaglandin receptor EP2 within the crosshairs of Salannin Autophagy antiinflammation, anticancer, and neuroprotection. Trends Pharmacol Sci. 2013;34:413423. 40. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;ten:181193.XING et al.41. Zhang C, Su ZY, Wang L, et al. Epigenetic Spergualin trihydrochloride Cancer blockade of neoplastic transformation by bromodomain and extraterminal (BET) domain protein inhibitor JQ1. Biochem Pharmacol. 2016;117:3545. 42. Zarneg.
